AB0868 A Descriptive Retrospective Study of Juvenile Idiopathic Arthritis Patients with Treated Biological

Background Biologic drugs are a mainstay in the treatment of juvenile idiopathic arthritis (JIA). The early use of these drugs allows controlling disease activity avoiding its consequences and improving the quality of life of patients. We know the main characteristics of our cohort of JIA patients treated with biologics. Objectives To describe the main characteristics of patients and biological treatments received during the last 5 years (2010–2015) in a pediatric unit of a children9s hospital. Methods Retrospective descriptive analytical study of patients diagnosed with JIA (as proposed by ILAR nomenclature) receiving biological treatment from 1 January 2010 to 30 June 2015. Data from medical records collected from patients who biological treatment received. Statistical analysis performed on SPSS.19.0 program. Results Total 105 patients treated with biological drugs in the last 5 years, 2/3 female (67 girls, 64%), 1/3 male (38 boys, 36%), mean age at diagnosis 5.3 years (DE ±3.95anos). The distribution of JIA: Oligoarticular arthritis 40% (42 patients). Polyarticular RF negative arthritis 22.9% (24 patients). Enthesitis-Related arthritis 15.2% (16 patients). Systemic 14.3% (15 patients). Polyarticular RF positive arthritis 3.8% (4 patients). Psoriatic arthritis 3.8% (4 patients). Patients with positive antinuclear antibodies (ANA) 24.8% (26 of 105 patients). Of the patients 32.2% (34 patients), i.e. 1/3 had uveitis, of these 41% (14 patients) had positive ANA. Initial treatment with methotrexate 78.1% (82 patients), methotrexate maintained 56.2 (59 patients), with adalimumab 37.1% (39 patients), etanercept 16.2% (17 patients), tocilizumab 2.9% (3 patients). Total received 123 biological treatments: adalimumab 49 (39.8%), etanercept 47 (39.2%), tocilizumab 16 (13%), anakinra 8 (3.5%) and canakinumab 3 (2.4%). Overall median time of monitoring 33.3 months (SD ±22.4 months). Continue with the drug 54 (43.9%), decrement regimen 50 (40.7%), replaced by inefficiency 15 (12.2%) (adalimumab 3, etanercept 4, anakinra 3, tocilizumab 5), suspended for toxicity 4 (3.3%) (anakinra 3, adalimumab 1). No deaths recorded. Conclusions The clinical features in this cohort of JIA patients treated with biologics are similar to those described in other “general series” that do not distinguish the type of treatment. The biological treatments used most often are etanercept and adalimumab, both with similar percentages (mainly in non-systemic JIA). The most commonly used drugs in systemic JIA are anakinra, tocilizumab and canakinumab. The biological treatments appear to be safe based on what has been described: few drugs had to be replaced by toxicity, and was not recorded death by the treatment or the disease itself. Disclosure of Interest None declared